Dapagliflozin mitigates oxidative stress, inflammatory, and histopathological markers of aging in mice

  • 0Department of Pharmacology, College of Pharmacy, Al-Esraa University, Baghdad, Iraq.

|

|

Summary

This summary is machine-generated.

Dapagliflozin shows anti-aging benefits in mice by reducing inflammation and improving antioxidant function. This study highlights its potential to mitigate age-related physiological decline.

Area Of Science

  • Gerontology and Pharmacology
  • Biomedical Research on Aging

Background

  • Aging is a complex biological process with significant research interest in interventions.
  • Developing strategies to slow aging and improve healthspan is a key scientific goal.

Purpose Of The Study

  • To evaluate the anti-aging effects of dapagliflozin (DAPA) in a D-galactose-induced aging mouse model.
  • To assess DAPA's impact on inflammatory markers and antioxidant efficacy.

Main Methods

  • Forty male Swiss albino mice were used, divided into control, aging model, Vitamin C, and dapagliflozin groups.
  • Aging was induced using D-galactose; treatments included saline, Vitamin C, and dapagliflozin.
  • Key aging biomarkers such as inflammatory mediators (TNF-α, IL-1β) and glutathione peroxidase (GSH-Px) were measured.

Main Results

  • Dapagliflozin treatment significantly reduced inflammatory mediators (TNF-α, IL-1β) compared to the aging model group.
  • No significant difference in inflammatory mediators or GSH-Px was observed between Vitamin C and dapagliflozin groups.
  • Dapagliflozin demonstrated beneficial effects including reduced cardiomyocyte hypertrophy, improved skin vitality, and enhanced antioxidant efficacy.

Conclusions

  • Dapagliflozin exhibits significant anti-aging properties in a mouse model.
  • The drug effectively mitigates key aging indicators, including inflammation and oxidative stress.
  • Dapagliflozin represents a potential therapeutic agent for combating age-related physiological changes.